Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen

H. Kobayashi, J. Lu, Esteban Celis

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The melanocyte-associated antigen gp100 constitutes one of the most attractive targets for T-cell-based immunotherapy against malignant melanoma. Although several MHC class I-restricted epitopes have been identified for CTLs, thus far, only one MHC class II T helper epitope (restricted by HLA-DR4) has been described in the literature. Using an algorithm to identify promiscuous helper T-cell epitopes, here we describe three additional MHC class II-restricted epitopes from gp100. Whereas one T helper epitope, gp100175-189, was restricted by the HLA-DR53 and DQw6 alleles, the T-cell responses to two other epitopes, gp10074-89 and gp100576-590, were restricted by HLA-DR7. Most interestingly, the newly identified helper T lymphocyte epitopes encompass or lie proximal to previously described CTL epitopes for this tumor-associated antigen. Together with the previously described HLA-DR4-restricted epitope, these T helper epitopes offer coverage for the majority of the human population. Moreover, the use of peptide vaccines containing both CTLs and T helper epitopes could offer therapeutic advantages over current approaches that focus solely on eliciting antitumor CTL responses.

Original languageEnglish (US)
Pages (from-to)7577-7584
Number of pages8
JournalCancer Research
Volume61
Issue number20
StatePublished - Oct 15 2001
Externally publishedYes

Fingerprint

gp100 Melanoma Antigen
T-Lymphocyte Epitopes
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Epitopes
HLA-DR4 Antigen
HLA-DR7 Antigen
T-Lymphocytes
Subunit Vaccines
Melanocytes
Immunotherapy
Melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. / Kobayashi, H.; Lu, J.; Celis, Esteban.

In: Cancer Research, Vol. 61, No. 20, 15.10.2001, p. 7577-7584.

Research output: Contribution to journalArticle

@article{d097e36d13034309b4c0cf35d56853f5,
title = "Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen",
abstract = "The melanocyte-associated antigen gp100 constitutes one of the most attractive targets for T-cell-based immunotherapy against malignant melanoma. Although several MHC class I-restricted epitopes have been identified for CTLs, thus far, only one MHC class II T helper epitope (restricted by HLA-DR4) has been described in the literature. Using an algorithm to identify promiscuous helper T-cell epitopes, here we describe three additional MHC class II-restricted epitopes from gp100. Whereas one T helper epitope, gp100175-189, was restricted by the HLA-DR53 and DQw6 alleles, the T-cell responses to two other epitopes, gp10074-89 and gp100576-590, were restricted by HLA-DR7. Most interestingly, the newly identified helper T lymphocyte epitopes encompass or lie proximal to previously described CTL epitopes for this tumor-associated antigen. Together with the previously described HLA-DR4-restricted epitope, these T helper epitopes offer coverage for the majority of the human population. Moreover, the use of peptide vaccines containing both CTLs and T helper epitopes could offer therapeutic advantages over current approaches that focus solely on eliciting antitumor CTL responses.",
author = "H. Kobayashi and J. Lu and Esteban Celis",
year = "2001",
month = "10",
day = "15",
language = "English (US)",
volume = "61",
pages = "7577--7584",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen

AU - Kobayashi, H.

AU - Lu, J.

AU - Celis, Esteban

PY - 2001/10/15

Y1 - 2001/10/15

N2 - The melanocyte-associated antigen gp100 constitutes one of the most attractive targets for T-cell-based immunotherapy against malignant melanoma. Although several MHC class I-restricted epitopes have been identified for CTLs, thus far, only one MHC class II T helper epitope (restricted by HLA-DR4) has been described in the literature. Using an algorithm to identify promiscuous helper T-cell epitopes, here we describe three additional MHC class II-restricted epitopes from gp100. Whereas one T helper epitope, gp100175-189, was restricted by the HLA-DR53 and DQw6 alleles, the T-cell responses to two other epitopes, gp10074-89 and gp100576-590, were restricted by HLA-DR7. Most interestingly, the newly identified helper T lymphocyte epitopes encompass or lie proximal to previously described CTL epitopes for this tumor-associated antigen. Together with the previously described HLA-DR4-restricted epitope, these T helper epitopes offer coverage for the majority of the human population. Moreover, the use of peptide vaccines containing both CTLs and T helper epitopes could offer therapeutic advantages over current approaches that focus solely on eliciting antitumor CTL responses.

AB - The melanocyte-associated antigen gp100 constitutes one of the most attractive targets for T-cell-based immunotherapy against malignant melanoma. Although several MHC class I-restricted epitopes have been identified for CTLs, thus far, only one MHC class II T helper epitope (restricted by HLA-DR4) has been described in the literature. Using an algorithm to identify promiscuous helper T-cell epitopes, here we describe three additional MHC class II-restricted epitopes from gp100. Whereas one T helper epitope, gp100175-189, was restricted by the HLA-DR53 and DQw6 alleles, the T-cell responses to two other epitopes, gp10074-89 and gp100576-590, were restricted by HLA-DR7. Most interestingly, the newly identified helper T lymphocyte epitopes encompass or lie proximal to previously described CTL epitopes for this tumor-associated antigen. Together with the previously described HLA-DR4-restricted epitope, these T helper epitopes offer coverage for the majority of the human population. Moreover, the use of peptide vaccines containing both CTLs and T helper epitopes could offer therapeutic advantages over current approaches that focus solely on eliciting antitumor CTL responses.

UR - http://www.scopus.com/inward/record.url?scp=0035887163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035887163&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 7577

EP - 7584

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -